Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1536990
Reference Type
Journal Article
Subtype
Review
Title
Effect of oral L-arginine supplementation on blood pressure: Ameta-analysis of randomized, double-blind, placebo-controlled trials
Author(s)
Dong, J; Qin, LiQ; Zhang, Z; Zhao, Y; Wang, J; Arigoni, F; Zhang, W
Year
2011
Is Peer Reviewed?
Yes
Journal
American Heart Journal
ISSN:
0002-8703
EISSN:
1097-6744
Volume
162
Issue
6
Page Numbers
959-965
Language
English
PMID
22137067
DOI
10.1016/j.ahj.2011.09.012
Web of Science Id
WOS:000298033300001
Abstract
BACKGROUND:
Previous studies suggest that L-arginine, an amino acid and a substrate of nitric oxide synthase, may have blood pressure (BP)-lowering effect. Because some studies were performed with limited number of patients with hypertension and therefore limited statistical power with sometimes inconsistent results, we aimed to examine the effect of oral L-arginine supplementation on BP by conducting a meta-analysis of randomized, double-blind, placebo-controlled trials.
METHODS:
PubMed, Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov databases were searched through June 2011 to identify randomized, double-blind, placebo-controlled trials of oral L-arginine supplementation on BP in humans. We also reviewed reference lists of obtained articles. Either a fixed-effects or, in the presence of heterogeneity, a random-effects model was used to calculate the combined treatment effect.
RESULTS:
We included 11 randomized, double-blind, placebo-controlled trials involving 387 participants with oral L-arginine intervention ranging from 4 to 24 g/d. Compared with placebo, L-arginine intervention significantly lowered systolic BP by 5.39 mm Hg (95% CI -8.54 to -2.25, P = .001) and diastolic BP by 2.66 mm Hg (95% CI -3.77 to -1.54, P < .001). Sensitivity analyses restricted to trials with a duration of 4 weeks or longer and to trials in which participants did not use antihypertensive medications yielded similar results. Meta-regression analysis suggested an inverse, though insignificant (P = .13), relation between baseline systolic BP and net change in systolic BP.
CONCLUSIONS:
This meta-analysis provides further evidence that oral L-arginine supplementation significantly lowers both systolic and diastolic BP.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity